- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Rosuvastatin not superior to Atorvastatin among patients with coronary artery disease: LODESTAR TRIAL
Coronary artery disease is a global threat making cardiac deaths a major concern. The major blood vessels i.e coronary arteries are incapable of sending enough blood, oxygen and nutrients to the heart muscle.
The LODESTAR trial was conducted to check the efficacy of Rosuvastatin and Atorvastatin over each other. The trial failed to show that rosuvastatin is superior to atorvastatin among patients with coronary artery disease. Rosuvastatin was associated with an excess incidence of initiation of diabetic medications and cataract operations. Based on this study, high-intensity atorvastatin therapy may be preferential to rosuvastatin. The trial is published in American College of Cardiology journal.
The researchers particularly aimed to evaluate rosuvastatin compared with atorvastatin among patients with coronary artery disease. A total of 4400 patients were included in the study. The study was designed to be a open labeled randomized parallel study. 2,204 of patients with coronary artery disease were randomized to rosuvastatin. A duration of 3 years of follow-up was kept. The mean age of patients was 65 years with 27% of them being females, and 33% had history of diabetes. The researchers included patients at least 19 years of age with coronary artery disease
Patients with pregnancy, Intolerance to statin or use of a medication that interacts with statin metabolism, risk for myopathy, limited life expectancy and low-density lipoprotein cholesterol (LDL-C) at enrollment, i.e 86 mg/dL were excluded.
The key findings of the study are
• The primary outcome such as death, stroke, myocardial infarction, or revascularization at 3 years, was 8.7% in the rosuvastatin group vs. 8.2% in the atorvastatin group (p = 0.58).
• High-intensity statin therapy dosing was achieved in 70.9% of the rosuvastatin group vs. 74.0% of the atorvastatin group (p = 0.022)
• LDL-C level <70 mg/dL at 3 years: 62.5% of the rosuvastatin group vs. 55.2% of the atorvastatin group (p < 0.001).
• Death at 3 years: 2.6% in the rosuvastatin group vs. 2.3% in the atorvastatin group (p = 0.57).
• Myocardial infarction at 3 years: 1.5% in the rosuvastatin group vs. 1.2% in the atorvastatin group (p = 0.37).
• Initiation of diabetic medication: 7.2% in the rosuvastatin group vs. 5.3% in the atorvastatin group (p = 0.031).
• Cataract operation: 2.5% in the rosuvastatin group vs. 1.5% in the atorvastatin group (p = 0.022)
The researchers ended that among patients with coronary artery disease, rosuvastatin was not superior to atorvastatin at preventing adverse cardiac events within 3 years. This lack of benefit was despite a higher frequency of subjects achieving LDL-C level <70 mg/dL at 3 years in the rosuvastatin group versus the atorvastatin group.
Reference: Anthony A. Bavry, MD, MPH, FACC; Rosuvastatin vs. Atorvastatin Treatment in Patients With Coronary Artery Disease – LODESTAR, Aug 25, 2023, Americ. Col. Cardio. Doi: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/08/23/19/37/lodestar.
MSc. Neuroscience
Niveditha Subramani a MSc. Neuroscience (Faculty of Medicine) graduate from University of Madras, Chennai. Ambitious in Neuro research having worked in motor diseases and neuron apoptosis is interested in more of new upcoming research and their advancement in field of medicine. She has an engrossed skill towards writing and her roles at Medical dialogue include Sr. Content writer. Her news covers new discoveries and updates in field of medicine. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751